Sun Pharmaceutical Industries Limited, an Indian multinational pharmaceutical company, has announced the launch of a new formulation in cough management in India, according to multiple sources.
The product, called Chericof 12, contains 30 mg dextromethorphan hydrobromide and 4 mg chlorpheniramine maleate.
Most cough syrups offer relief for 6 to 8 hours so patients have to take them at least 3 to 4 times a day.
Experts believe that frequent dosing with couch syrups could lead to patient inconvenience and non-compliance to the treatment, affecting the drug’s efficacy.
Chericof 12 is now the first prescription cough syrup in India, which provides relief for up to 12 hours. The product is manufactured using Polistirex technology for sustained release of the drug.
The technology involves the combination of dextromethorphan hydrobromide and chlorpheniramine maleate with resins.
Dextromethorphan hydrobromide is a cough suppressant and chlorpheniramine maleate is an antihistamine. A combination of these drugs is often used for the treatment of cough, sneezing, and runny nose caused by the common cold.
Dextromethorphan, which is a non-opioid cough suppressant, works on a certain part of the brain to help you stop coughing, according to WebMD. On the other hand, chlorpheniramine works by blocking the effects of histamine, a substance responsible for causing allergy symptoms.
Combining the drugs with the Polistirex technology provides sustained release and reduces the bitter taste making the syrup more palatable.
The product has been approved for patients aged 6 and above.
Kirti Ganorkar, CEO, India business, Sun Pharma said, “The Polistirex technology used in Chericof 12 helps in improving patient compliance and avoids the need for frequent dosing.” Sun Pharma is the world’s fourth-largest pharmaceutical company that specializes in developing generic drugs. It is one of India’s top pharmaceutical companies.
